Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

Conditions: Chronic Obstructive Pulmonary Disease, Physical Activity, Health Behavior
Interventions: Telephonic health coaching; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Asthma, Smoking Cessation
Interventions: Cessation Counseling; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 27
States / cities: Tucson, Arizona • Riverside, California • San Diego, California + 24 more

Conditions: Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions: LungGuard, BAROGuard; Device
Lead sponsor: Paragonix Technologies; Industry
Eligibility: Not listed
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more

Conditions: Hyperoxia
Interventions: 60% oxygen, 100% oxygen; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cystic Fibrosis
Interventions: Losartan, placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 12 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Miami, Florida • Kansas City, Kansas + 1 more

Conditions: Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 1,394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more

Conditions: Head and Neck Cancer, Lung Cancer, Lymphoma
Interventions: Amifostine administered subcutaneously; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Lung Carcinoma
Interventions: Survey Administration, Electronic Health Record Review; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumor, Lymphoma
Interventions: Ad-p53; Drug
Lead sponsor: MultiVir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Morristown, New Jersey

Conditions: Lung Cancer
Interventions: Blood and Tissue studies; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Long COVID
Interventions: MY-Skills for Long COVID; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lung Cancer
Interventions: docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy; Drug · Other · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neuromuscular Diseases
Interventions: Oscillation and Lung Expansion (OLE) therapy; Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 5 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Segmentectomy
Interventions: Segmentectomy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis, Cellulitis, Abdominal Aortic Aneurysm, Acute Cholecystitis, Peritoneal Free Fluid, Hydronephrosis, Pleural Effusion, Urinary Retention
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: vorinostat, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: Green Bay, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 1 more

Conditions: ALS
Interventions: remote pulmonary function testing, standard pulmonary function testing; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, thalidomide, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 235
States / cities: Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more

Conditions: Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: San Carlos, California

Conditions: Cystic Fibrosis
Interventions: hydroxychloroquine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: ME/CFS, Long COVID, PASC
Interventions: Pyridostigmine, Low-Dose Naltrexone, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Physical Activity Coaching in Chronic Obstructive Pulmonary Disease (COPD)

Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy

The ROAM Research Study Therapy (LTOT) Version

Losartan and Inflammation in Cystic Fibrosis

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Subcutaneous Amifostine Safety Study

Improving Lung Cancer Screening Adherence by Overcoming Barriers for Vulnerable Populations

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer

Merging Yoga and Self-Management Skills for Symptoms of Long COVID

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Oscillation and Lung Expansion (OLE) Therapy for Treatment of Neuromuscular Disease (NMD) Patients

Segmentectomy After Induction Therapy (SAINT)

Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot)

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

BESPOKE Study of ctDNA Guided Immunotherapy

Hydroxychloroquine in Cystic Fibrosis

LIFT: Life Improvement Trial